News and History

Search (e.g. by company, location, key word)
Categories
Location
1-20 of 10,918 results

  • Biogen to Acquire Apellis for $5.6 billion, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease

    On Mar. 31, 2026, Biogen and Apellis Pharmaceuticals announced the companies have entered into a definitive agreement under

    Read More: Biogen to Acquire Apellis for $5.6 billion, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease

  • Lilly to acquire Centessa Pharma to advance treatments for sleep-wake disorders in deal worth up to $7.8 Billion

    On Mar. 31, 2026, Eli Lilly and Centessa Pharmaceuticals, a clinical-stage company developing a new class of medicines

    Read More: Lilly to acquire Centessa Pharma to advance treatments for sleep-wake disorders in deal worth up to $7.8 Billion

  • FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

    On Mar. 30, 2026, Biogen announced that the High Dose Regimen of SPINRAZA® (nusinersen), which is comprised of

    Read More: FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

  • China biotech deals hit record as innovative drugs draw interest of multinationals

    On Mar. 29, 2026, The South China Morning Post reported the cross-border outlicensing activities of Chinese biotech firms

    Read More: China biotech deals hit record as innovative drugs draw interest of multinationals

  • Insilico Medicine secures $2.75 billion drug collaboration with Eli Lilly

    On Mar. 29, 2026, generative-AI drug developer Insilico Medicine announced that it has ​agreed to a global licensing

    Read More: Insilico Medicine secures $2.75 billion drug collaboration with Eli Lilly

  • NIH restrictions on foreign research partnerships significantly impacted 1 in 4 U.S. scientists

    On Mar. 27, 2026, a STAT survey conducted of nearly 1,000 National Institutes of Health (NIH) -supported scientists,

    Read More: NIH restrictions on foreign research partnerships significantly impacted 1 in 4 U.S. scientists

  • Novartis to acquire Excellergy for $2 Billion, building on allergy leadership with next-generation anti-IgE innovation

    On Mar. 27, 2026, Novartis announced an agreement to acquire Excellergy, a private biotech company developing next-generation anti-IgE

    Read More: Novartis to acquire Excellergy for $2 Billion, building on allergy leadership with next-generation anti-IgE innovation

  • Implantable ‘Living Pharmacy’ Produces Multiple Drugs Inside the Body

    On Mar. 27, 2026, A multi-institutional team of scientists, co-led by Northwestern University, has taken a crucial step

    Read More: Implantable ‘Living Pharmacy’ Produces Multiple Drugs Inside the Body

  • Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

    On Mar. 27, 2026, Rocket Pharmaceuticals announced that the U.S. Food and Drug Administration(FDA) has granted accelerated approval

    Read More: Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

  • PTAB sides with Broad Institute over University of California on patent priority for use of CRISPR in eukaryotic cells

    On Mar. 26, 2026, the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (USPTO and PTAB,

    Read More: PTAB sides with Broad Institute over University of California on patent priority for use of CRISPR in eukaryotic cells

  • Largest Animal Health Emergency in U.S. History Continues as HPAI Devastates Indiana

    On Mar. 26, 2026, Indiana’s poultry industry continues to face significant challenges as outbreaks of highly pathogenic avian

    Read More: Largest Animal Health Emergency in U.S. History Continues as HPAI Devastates Indiana

  • Merck to Acquire Terns Pharmaceuticals for $5.7 Billion, Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia

    On Mar. 25, 2026, Merck, and Terns Pharmaceuticals, a clinical-stage oncology company, announced that the companies have entered

    Read More: Merck to Acquire Terns Pharmaceuticals for $5.7 Billion, Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia

  • ‘Dead End’: Radical 20-Year Study Reveals Genetic Cloning Hits a Limit

    On Mar. 25, 2026, researchers, led by scientists at the University of Yamanashi in Japan, cloned a single

    Read More: ‘Dead End’: Radical 20-Year Study Reveals Genetic Cloning Hits a Limit

  • WHO Data Show Pertussis (Whooping Cough) Rising in Western Pacific and Europe

    On Mar. 25, 2026, according to the latest data published by the World Health Organization (WHO), globally, 941,582

    Read More: WHO Data Show Pertussis (Whooping Cough) Rising in Western Pacific and Europe

  • Canine companions: revealing the genetic history of our first friends 

    On Mar. 24, 2026, researchers at the Francis Crick Institute report that the largest ancient DNA study of

    Read More: Canine companions: revealing the genetic history of our first friends 

  • DNA in dirt is shaking up the study of human origins

    On Mar. 24, 2026, a study published in Nature describes how researchers are pulling clues from genetic material

    Read More: DNA in dirt is shaking up the study of human origins

  • UCB to Invest $2 Billion in Georgia, Establish First U.S. Manufacturing Facility

    On Mar. 24, 2026, Governor Brian P. Kemp announced that global biopharmaceutical giant UCB, is planning a significant

    Read More: UCB to Invest $2 Billion in Georgia, Establish First U.S. Manufacturing Facility

  • Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

    On Mar. 24, 2026, Pfizer and Valneva announced topline results from the Phase 3 VALOR “Vaccine Against Lyme

    Read More: Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

  • Largest Animal Health Emergency in U.S. History Continues as HPAI Devastates Indiana

    On Mar. 23, 2026, it was reported that since the beginning of March, highly pathogenic avian influenza has

    Read More: Largest Animal Health Emergency in U.S. History Continues as HPAI Devastates Indiana

  • Novartis to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline for $3 Billion

    On Mar. 20, 2026, Novartis announced an agreement with Synnovation Therapeutics, to acquire SNV4818, a pan-mutant‑selective PI3Kα inhibitor,

    Read More: Novartis to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline for $3 Billion